Dongqiang Zeng

Dongqiang Zeng

Auto-generated profile, based on publicly available information

Dongqiang Zeng

Shenzhen Hospital of Southern Medical University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
DZDongqiang Zeng
Dongqiang Zeng
MLMeiyi Li
Meiyi Li
RZRui Zhou
Rui Zhou
JZJingwen Zhang
Jingwen Zhang
HSHuiying Sun
Huiying Sun
WLWangjun Liao
Wangjun Liao
Tumor microenvironment (TME) cells constitute a vital element of tumor tissue. Increasing evidence has elucidated their clinicopathologic significance in predicting outcomes and therapeutic efficacy. Nonetheless, no studies have reported a systematic analysis of cellular interactions in the TME. In this study, we comprehensively estimated the TME infiltration patterns of 1,524 gastric cancer patients and systematically correlated the TME phenotypes with genomic characteristics and clinicopathologic features of gastric cancer using two proposed computational algorithms. Three TME phenotypes were defined, and the TMEscore was constructed using principal component analysis algorithms. The high TMEscore subtype was characterized by immune activation and response to virus and IFNγ. Activation of transforming growth factor β, epithelial–mesenchymal transition, and angiogenesis pathways were observed in the low TMEscore subtype, which are considered T-cell suppressive and may be responsible for significantly worse prognosis in gastric cancer [hazard ratio (HR), 0.42; 95% confidence interval (CI), 0.33–0.54; P < 0.001]. Multivariate analysis revealed that the TMEscore was an independent prognostic biomarker, and its value in predicting immunotherapeutic outcomes was also confirmed (IMvigor210 cohort: HR, 0.63; 95% CI, 0.46–0.89; P = 0.008; GSE78220 cohort: HR, 0.25; 95% CI, 0.07–0.89; P = 0.021). Depicting a comprehensive landscape of the TME characteristics of gastric cancer may, therefore, help to interpret the responses of gastric tumors to immunotherapies and provide new strategies for the treatment of cancers.

10 August 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
DZDongqiang Zeng
Dongqiang Zeng
JWJiani Wu
Jiani Wu
HLHuiyan Luo
Huiyan Luo
YLYong Li
Yong Li
JXJian Xiao
Jian Xiao
WLWangjun Liao
Wangjun Liao
Background Durable efficacy of immune checkpoint blockade (ICB) occurred in a small number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of response to ICB remains unclear. Methods We developed an open-source TMEscore R package, to quantify the tumor microenvironment (TME) to aid in addressing this dilemma. Two advanced gastric cancer cohorts (RNAseq, N=45 and NanoString, N=48) and other advanced cancer (N=534) treated with ICB were leveraged to investigate the predictive value of TMEscore. Simultaneously, multi-omics data from The Cancer Genome Atlas of Stomach Adenocarcinoma (TCGA-STAD) and Asian Cancer Research Group (ACRG) were interrogated for underlying mechanisms. Results The predictive capacity of TMEscore was corroborated in patient with mGC cohorts treated with pembrolizumab in a prospective phase 2 clinical trial (NCT02589496, N=45, area under the curve (AUC)=0.891). Notably, TMEscore, which has a larger AUC than programmed death-ligand 1 combined positive score, tumor mutation burden, microsatellite instability, and Epstein-Barr virus, was also validated in the multicenter advanced gastric cancer cohort using NanoString technology (N=48, AUC=0.877). Exploration of the intrinsic mechanisms of TMEscore with TCGA and ACRG multi-omics data identified TME pertinent mechanisms including mutations, metabolism pathways, and epigenetic features. Conclusions Current study highlighted the promising predictive value of TMEscore for patients with mGC. Exploration of TME in multi-omics gastric cancer data may provide the impetus for precision immunotherapy.

3 July 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
YYYunfang Yu
Yunfang Yu
DZDongqiang Zeng
Dongqiang Zeng
QOQiyun Ou
Qiyun Ou
SLShengbo Liu
Shengbo Liu
ALAnlin Li
Anlin Li
HYHerui Yao
Herui Yao
Advances in immuno-oncology are changing the standard of care for non–small cell lung cancer (NSCLC) through immunotherapies, including tumor vaccines, cellular immunotherapies, and immune checkpoint inhibitors (ICIs), that aim to establish or enhance effective immune responses toward a tumor.1,2 However, immunotherapy has produced inconsistent results in previous randomized clinical trials (RCTs). In the KEYNOTE-024,3 CheckMate-057,4 and TIME5 trials and the study by Li et al,6 immunotherapies were found to significantly improve overall survival (OS) and progression-free survival (PFS) rates compared with chemotherapy in patients with advanced NSCLC, but inconsistent survival outcomes were shown in the CheckMate-026 trial7 and the studies by Takayama et al8 and Wu et al.9 Additionally, important questions remain regarding which immunotherapeutic strategy can be deployed to the best benefit.

19 December 2018 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
RZRui Zhou
Rui Zhou
JZJingwen Zhang
Jingwen Zhang
DZDongqiang Zeng
Dongqiang Zeng
HSHuiying Sun
Huiying Sun
XRXiaoxiang Rong
Xiaoxiang Rong
WLWangjun Liao
Wangjun Liao
Tumour-infiltrating immune cells are a source of important prognostic information for patients with resectable colon cancer. We developed a novel immune model based on systematic assessments of the immune landscape inferred from bulk tumor transcriptomes of stage I–III colon cancer patients. The “Cell type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT)” algorithm was used to estimate the fraction of 22 immune cell types from six microarray public datasets. The random forest method and least absolute shrinkage and selection operator model were then used to establish immunoscores for diagnosis and prognosis. By comparing immune cell compositions in samples of 870 colon cancer patients and 70 normal controls, we constructed a diagnostic model, designated the diagnostic immune risk score (dIRS), that showed high specificity and sensitivity in both the training [area under the curve (AUC) = 0.98, p < 0.001] and validation (AUC 0.96, p < 0.001) sets. We also established a prognostic immune risk score (pIRS) that was found to be an independent prognostic factor for relapse-free survival in every series (training: HR 2.23; validation: HR 1.65; entire: HR 2.01; p < 0.001 for all), which showed better prognostic value than TNM stage. In addition, integration of the pIRS with clinical characteristics in a composite nomogram showed improved accuracy of relapse risk prediction, providing a higher net benefit than TNM stage, with well-fitted calibration curves. The proposed dIRS and pIRS models represent promising novel signatures for the diagnosis and prognosis prediction of colon cancer.

9 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
DZDong-Qiang Zeng
Dong-Qiang Zeng
YYYun-Fang Yu
Yun-Fang Yu
QOQi-Yun Ou
Qi-Yun Ou
XLXiao-Yin Li
Xiao-Yin Li
RZRu-Zhi Zhong
Ru-Zhi Zhong
QHQiu-Gen Hu
Qiu-Gen Hu
Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer

25 April 2018 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
DZD. Zeng
D. Zeng
RZR. Zhou
R. Zhou
YYY. Yu
Y. Yu
YLY. Luo
Y. Luo
JZJ. Zhang
J. Zhang
WLWangjun Liao
Wangjun Liao
Background: Increasing evidence has indicated an association between immune infiltration in gastric cancer and clinical outcome. However, reliable prognostic signatures, based on systematic assessments of the immune landscape inferred from bulk tumour transcriptomes, have not been established. The aim was to develop an immune signature, based on the cellular composition of the immune infiltrate inferred from bulk tumour transcriptomes, to improve the prognostic predictions of gastric cancer.Methods: Twenty-two types of immune cell fraction were estimated based on large public gastric cancer cohorts from the Gene Expression Omnibus using CIBERSORT. An immunoscore based on the fraction of immune cell types was then constructed using a least absolute shrinkage and selection operator (LASSO) Cox regression model.Results: Using the LASSO model, an immunoscore was established consisting of 11 types of immune cell fraction. In the training cohort (490 patients), significant differences were found between high- and low-immunoscore groups in overall survival across and within subpopulations with an identical TNM stage. Multivariable analysis revealed that the immunoscore was an independent prognostic factor (hazard ratio 1·92, 95 per cent c.i. 1·54 to 2·40). The prognostic value of the immunoscore was also confirmed in the validation (210) and entire (700) cohorts.Conclusion: The proposed immunoscore represents a promising signature for estimating overall survival in patients with gastric cancer.